Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sapien Heart Valve Gets FDA Panel Nod For High-Risk Surgical Patients

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences’ first-to-market transcatheter valve is safe and effective, and its benefits outweigh its risks in an expanded patient population, an FDA advisory panel says.


Related Content

ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve
New Products In Brief
Medical Device Market & Industry Briefs, August 2012
Edwards’ Sapien Ramp-Up Successful, But Medicare Policy Makes For Some Hurdles
Edwards’ Pursuit Of Transcatheter Mitral Valve Repair Options Continues, CEO Says
CMS Policy Sets Boundaries On Transcatheter Valve Procedure
Two-Year Sapien Data Affirms Durability, And The Importance Of Avoiding Leaks
Transcatheter Valves: Tough Love For Transapical Placement Method At TCT
Edwards Wins Approval For Sapien Just In Time For TCT
Getting Set For Sapien: With Data In, Discussion Moves To Adoption Dynamics





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts